Because of these, some of the inhibitors (ligands) of Dopamine Transporters and the receptor (Dopamine transporter elucidates antidepressant mechanism) targeting schizophrenia that is well documented in the CHEMBL Database [19] and the Protein Data Bank respectively were studied as to harness the structural features influencing the observed antipsychotic activity of the inhibitors as well as to elucidate the binding mode and molecular interactions between the ligands and the receptor targeting schizophrenia. The gene discussed is SLC6A3; the disease is schizophrenia.